MA28738B1 - Composes, compositions et procedes associes - Google Patents

Composes, compositions et procedes associes

Info

Publication number
MA28738B1
MA28738B1 MA29616A MA29616A MA28738B1 MA 28738 B1 MA28738 B1 MA 28738B1 MA 29616 A MA29616 A MA 29616A MA 29616 A MA29616 A MA 29616A MA 28738 B1 MA28738 B1 MA 28738B1
Authority
MA
Morocco
Prior art keywords
compositions
compounds
related methods
heart failure
cardiac
Prior art date
Application number
MA29616A
Other languages
English (en)
Inventor
Bradley P Morgan
Alex Muci
Pu-Ping Lu
Erica Kraynack
Todd Tochimoto
David Morgans
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35785669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28738(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MA28738B1 publication Critical patent/MA28738B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
MA29616A 2004-06-17 2007-01-17 Composes, compositions et procedes associes MA28738B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58119704P 2004-06-17 2004-06-17

Publications (1)

Publication Number Publication Date
MA28738B1 true MA28738B1 (fr) 2007-07-02

Family

ID=35785669

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29616A MA28738B1 (fr) 2004-06-17 2007-01-17 Composes, compositions et procedes associes

Country Status (33)

Country Link
US (12) US7507735B2 (fr)
EP (2) EP2862859B1 (fr)
JP (2) JP5080970B2 (fr)
KR (1) KR101276136B1 (fr)
CN (1) CN101035525A (fr)
AR (1) AR053405A1 (fr)
AU (1) AU2005264988B2 (fr)
BR (1) BRPI0512193B8 (fr)
CA (1) CA2570999C (fr)
CY (1) CY1115716T1 (fr)
DK (2) DK1765327T3 (fr)
EA (1) EA016138B1 (fr)
EC (1) ECSP077180A (fr)
ES (2) ES2522579T3 (fr)
HK (2) HK1101060A1 (fr)
HR (1) HRP20141048T1 (fr)
IL (1) IL180026A (fr)
MA (1) MA28738B1 (fr)
ME (1) ME01942B (fr)
MX (1) MXPA06014495A (fr)
MY (1) MY144470A (fr)
NO (1) NO340030B1 (fr)
NZ (1) NZ552404A (fr)
PE (1) PE20060438A1 (fr)
PL (2) PL216049B1 (fr)
PT (1) PT1765327E (fr)
RS (1) RS53600B1 (fr)
RU (1) RU2410384C2 (fr)
SG (1) SG149027A1 (fr)
SI (1) SI1765327T1 (fr)
TW (1) TWI359812B (fr)
WO (1) WO2006009726A2 (fr)
ZA (1) ZA200700351B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495337B1 (en) * 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
AU2004206860B2 (en) * 2003-01-14 2010-03-18 Cytokinetics, Inc. Compounds, compositions and methods
RU2410384C2 (ru) 2004-06-17 2011-01-27 Цитокинетикс, Инк. Соединения, композиции и способы их использования
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006062982A2 (fr) * 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Inhibiteurs urée de map kinases
JP2008523072A (ja) * 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959960B1 (fr) * 2005-12-15 2013-04-10 Cytokinetics, Inc. Entites chimiques, compositions et procedes
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959962A2 (fr) 2005-12-16 2008-08-27 Cytokinetics, Inc. Entites chimiques, compositions et methodes
EP1962852B1 (fr) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Composes, compositions et methodes
CA2635888A1 (fr) * 2006-01-04 2007-07-19 Locus Pharmaceuticals, Inc. Inhibiteurs de proteine kinases
WO2007110449A1 (fr) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Composés de benzènesulfonamide et utilisation de ceux-ci
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) * 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2008124118A1 (fr) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Composés benzènesulfonylés et leur utilisation
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
JP2014515839A (ja) 2011-04-20 2014-07-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 最小角度依存性を有する表示装置及びイメージング用のスペクトルフィルタリング
CN102288601B (zh) * 2011-05-16 2012-12-12 中国药科大学 一种肌球蛋白atp酶活性微量测定方法及其应用
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US9709649B2 (en) * 2013-02-08 2017-07-18 Regents Of The University Of Minnesota System and method for assessing adenosine triphosphate hydrolysis rate using double saturation transfer magnetic resonance imaging and spectroscopy
EP2968180B1 (fr) 2013-03-14 2019-04-24 Amgen Inc. Composés hétérocycliques et leurs utilisations
CA2902646C (fr) 2013-03-14 2022-08-16 Cytokinetics, Inc. Composes heterocycliques et leurs utilisations
US9547107B2 (en) 2013-03-15 2017-01-17 The Regents Of The University Of Michigan Dye and pigment-free structural colors and angle-insensitive spectrum filters
WO2015142001A2 (fr) * 2014-03-21 2015-09-24 충남대학교산학협력단 Composé doté d'une action cardiotonique et composition pharmaceutique permettant de prévenir ou de traiter l'insuffisance cardiaque et contenant ledit composé
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
SG10201913047UA (en) * 2015-01-22 2020-02-27 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
KR20160108281A (ko) 2016-09-06 2016-09-19 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
EP3523271B1 (fr) 2016-10-10 2020-12-09 Basf Se Modification catalytique au moyen d'ions de métal de terres rares, de métal alcalino-terreux ou de métal alcalin dans l'hydrogénation en phase liquide continue de composés nitrés
US10256925B2 (en) * 2017-01-19 2019-04-09 Samsung Electronics Co., Ltd. Methods and wireless communication systems for wireless re-calibration of RF components of communication devices
LT3645518T (lt) 2017-06-30 2021-10-11 Amgen Inc. Omekamitivo mekarbilo sintezė
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
CA3075669A1 (fr) 2017-09-13 2019-03-21 Amgen Inc. Composes activateurs de bisamide sarcomere et leurs utilisations
AU2019208331B2 (en) * 2018-01-19 2024-05-02 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
CA3108800A1 (fr) 2018-08-17 2020-02-20 Amgen Inc. Sel et formes cristallines d'omecamtiv mecarbil
SG11202101769YA (en) 2018-08-31 2021-03-30 Cytokinetics Inc Cardiac sarcomere inhibitors
EP4045492A1 (fr) 2019-09-19 2022-08-24 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
EP4031541A1 (fr) 2019-09-19 2022-07-27 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
US20220411374A1 (en) * 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
WO2022177927A1 (fr) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
BR112023017461A2 (pt) 2021-03-04 2023-09-26 Cytokinetics Inc Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
WO2024081611A1 (fr) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Méthodes de traitement de l'insuffisance cardiaque par administration d'activateurs de sarcomère cardiaque
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US397782A (en) * 1889-02-12 Plunger water-closet
NL254871A (fr) 1959-08-14
US3939169A (en) 1971-03-29 1976-02-17 Imperial Chemical Industries Limited Alkylene bis(pyridiniumareylene quaternary salts)
GB1339764A (en) * 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
DE2942930A1 (de) 1979-10-24 1981-05-27 Basf Ag, 6700 Ludwigshafen Substituierte harnstoffe, deren herstellung und verwendung als herbizide
DE3147879A1 (de) 1981-12-03 1983-06-16 Basf Ag, 6700 Ludwigshafen 1,3,5-triazinone, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
EP0081142B1 (fr) 1981-12-03 1986-06-25 BASF Aktiengesellschaft 1,3,5-Triazinones, procédé pour leur préparation et leur utilisation pour lutter contre la croissance indésirable de plantes
AU2818584A (en) 1983-03-29 1984-10-25 Fmc Corporation N-phenyl-n-(pyridinyl-n-oxide)urea plant regulators
US4787931A (en) 1984-03-06 1988-11-29 Fmc Corporation N-phenyl-N'-(pyridinyl-N-oxide)urea plant regulators
US4672066A (en) 1985-04-22 1987-06-09 Hoffmann-La Roche Inc. Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
GEP20001968B (en) 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
JPH07503737A (ja) * 1992-05-28 1995-04-20 フアイザー・インコーポレイテツド アシル補酵素ａ：コレステロールアシルトランスフェラーゼ（ａｃａｔ）の阻害剤としての新規なｎ−アリールおよびｎ−ヘテロアリール尿素誘導体
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0634402A1 (fr) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Dérivés d'isoquinolinone, leur production et utilisation
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
JPH10510512A (ja) 1994-10-04 1998-10-13 藤沢薬品工業株式会社 尿素誘導体とａｃａｔ阻害剤としての用途
DE69533174T2 (de) * 1994-10-27 2004-11-18 Fujisawa Pharmaceutical Co., Ltd. Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten
US6010026A (en) 1994-11-22 2000-01-04 Aluminum Company Of America Assembly of aluminum can and threaded sleeve
US5556969A (en) 1994-12-07 1996-09-17 Merck Sharp & Dohme Ltd. Benzodiazepine derivatives
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
GB9504361D0 (en) 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
GB9511355D0 (en) 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
US5972975A (en) 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US6005008A (en) 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
DK0915859T3 (da) * 1996-07-23 2003-03-03 Neurogen Corp Visse substituerede benzylaminderivater; en ny klasse af Neuropeptid Y1-specifikke ligander
IT1284198B1 (it) 1996-07-30 1998-05-08 Beniamino Anzalone Carne vegetale
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
AUPO390996A0 (en) 1996-11-29 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO1998041510A1 (fr) 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Nouveaux derives du benzolactame et compositions medicamenteuses les contenant
WO1998050346A2 (fr) 1997-04-18 1998-11-12 Smithkline Beecham Plc Derives d'acetamide et d'uree, procede de preparation et utilisation de ces derives dans le traitement des troubles du systeme nerveux central
JP4344960B2 (ja) 1997-05-23 2009-10-14 バイエル、コーポレイション アリール尿素によるｐ３８キナーゼ活性の阻害
AU7585598A (en) 1997-05-23 1998-12-11 Bayer Corporation Raf kinase inhibitors
WO1999023090A1 (fr) * 1997-11-05 1999-05-14 Choongwae Pharma Corporation Nouveau derive de genepine faisant montre d'une activite protectrice du foie
CN1149085C (zh) 1997-12-22 2004-05-12 拜尔有限公司 用取代杂环脲抑制raf激酶
DE1042305T1 (de) 1997-12-22 2001-04-19 Bayer Ag HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
EP1041982B1 (fr) 1997-12-22 2011-10-19 Bayer HealthCare LLC Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques substituees
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
DE1049664T1 (de) 1997-12-22 2001-05-03 Bayer Ag Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
JP4405602B2 (ja) 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
CN1311773A (zh) 1998-06-08 2001-09-05 先灵公司 神经肽y5受体拮抗剂
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
JP3594317B2 (ja) * 1998-08-11 2004-11-24 住友製薬株式会社 ナフチリジン誘導体
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
EP1158985B1 (fr) 1999-01-13 2011-12-28 Bayer HealthCare LLC DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US6402960B1 (en) 1999-03-01 2002-06-11 The Regents Of The University Of California Thiacrown polymers for removal of mercury from waste streams
DE19921498A1 (de) 1999-05-08 2000-11-16 Clariant Gmbh Verfahren zur Herstellung von wäßrigen Diazoniumsalzlösungen
JP4162406B2 (ja) 1999-07-09 2008-10-08 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ヘテロアリール置換ウレア化合物の新規合成方法
AU6314900A (en) 1999-07-26 2001-02-13 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
AU7446600A (en) 1999-10-01 2001-05-10 Japan Energy Corporation Novel diarylamide derivatives and use thereof as medicines
DE60036726T2 (de) 1999-11-16 2008-02-07 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Harnstoff derivate als entzündungshemmende mittel
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
JP2001278886A (ja) * 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
CA2413274A1 (fr) 2000-06-21 2001-12-27 George V. Delucca N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
GB0015904D0 (en) 2000-06-28 2000-08-23 Hoffmann La Roche Inhibitors of HPV E1 helicase enzyme
AU2001271631A1 (en) * 2000-06-30 2002-01-14 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl aminoacyl pyrrole compounds
AU2001269540A1 (en) 2000-07-18 2002-01-30 Sumitomo Pharmaceuticals Co. Ltd. Serotonin reuptake inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
WO2002059080A2 (fr) 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Composes de liaison de la cyclophiline carboxylique trisubstituee et leur utilisation
JP2002220338A (ja) 2001-01-26 2002-08-09 Banyu Pharmaceut Co Ltd ビアリールウレア化合物又はその塩を有効成分として含有するＣｄｋ４及び／又はＣｄｋ６阻害剤
GB0117950D0 (en) 2001-02-16 2001-09-19 Aventis Pharma Inc Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
JP4366936B2 (ja) 2001-04-20 2009-11-18 バイエル コーポレイション キノリル、イソキノリルまたはピリジル尿素を使用するｒａｆキナーゼの阻害
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
EP1395561A1 (fr) 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Composes de carbamate et d'oxamide inhibant la production de cytokine
AU2002346048A1 (en) 2001-06-07 2002-12-16 Merck And Co., Inc. Benzodiazepine bradykinin antagonists
ATE360417T1 (de) 2001-07-11 2007-05-15 Boehringer Ingelheim Pharma Methode zur behandlung von zytokinvermittelten erkrankungen
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
WO2003022820A1 (fr) 2001-09-06 2003-03-20 Bristol-Myers Squibb Pharma Company. Cyclopropane hetero-aromatique substitue utilise comme hormone adrenocorticotrope
EP1426360A4 (fr) 2001-09-12 2006-04-12 Kaken Pharma Co Ltd Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant
US7320126B2 (en) * 2001-11-06 2008-01-15 Sandisk Corporation Implementation of in system programming to update firmware on memory cards
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
EP1503986B1 (fr) 2001-12-21 2015-09-30 Cytokinetics, Inc. Compositions et methodes permettant de traiter l'insuffisance cardiaque
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1472248A1 (fr) 2002-01-17 2004-11-03 Eli Lilly And Company Modulateurs de recepteurs de l'acetylcholine
US7408067B2 (en) 2002-01-17 2008-08-05 Merck + Co., Inc. Aza-cyclic compounds as modulators of acetylcholine receptors
ES2425739T3 (es) 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
DE10208986A1 (de) 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
WO2003074501A1 (fr) 2002-03-07 2003-09-12 Sds Biotech K.K. Derive d'isoxazole alkylamine substitue et fongicide a usage dans l'agriculture et l'horticulture
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
ZA200406763B (en) 2002-03-28 2005-09-30 Applied Research Systems Thiazolidine carboxamide derivatives as modulatorsof the prostaglandin F receptor.
JPWO2003082808A1 (ja) 2002-04-03 2005-08-04 住友製薬株式会社 ベンズアミド誘導体
AR040405A1 (es) 2002-04-18 2005-04-06 Schering Corp Derivados de bencimidazol utiles como antagonistas de histamina h3
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
PL373371A1 (en) 2002-04-23 2005-08-22 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
AU2003229538A1 (en) 2002-05-17 2003-12-02 Lica Pharmaceuticals A/S Aminoalkoxy-functional chalcones
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MXPA05000193A (es) 2002-06-24 2005-04-08 Schering Corp Derivados de indol utiles como antagonistas de la histamina h2.
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
CA2493026C (fr) * 2002-07-31 2011-05-24 Schering Aktiengesellschaft Anthranylamidopyrimidines inhibant vegfr-2 et vegfr-3
GB0218147D0 (en) 2002-08-05 2002-09-11 Oxford Glycosciences Uk Ltd Novel compounds
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
WO2004022561A1 (fr) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines tenant lieu d'inhibiteurs de kinases dependantes de la cycline
US6915814B2 (en) * 2002-09-04 2005-07-12 Dara Cheng Transparent pipe trap with means of enhancing the biodegradation of sink effluents
CA2498291C (fr) 2002-09-10 2009-04-07 Pfizer Products Inc. Composes diazabicycliques utilises dans le traitement de troubles associes au snc
ATE361739T1 (de) 2002-10-29 2007-06-15 Oreal Haarpflegemittel enthaltend eine styrylpyrazole verbindung
AU2004206860B2 (en) 2003-01-14 2010-03-18 Cytokinetics, Inc. Compounds, compositions and methods
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
AU2003902073A0 (en) 2003-05-01 2003-05-15 Kevin Raymond Deguara A lighting substrate
EP1620091B1 (fr) 2003-05-05 2010-03-31 Probiodrug AG Inhibiteurs de glutaminyl-cyclase
WO2004101529A1 (fr) 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. Compose heterocyclique azote et son utilisation medicale
PL1636585T3 (pl) 2003-05-20 2008-10-31 Bayer Healthcare Llc Diarylowe pochodne mocznika inhibowane kinazą
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
CA2546673A1 (fr) 2003-11-28 2005-06-09 Novartis Ag Derives de diaryluree utilises en traitement de maladies dependant de proteines kinases
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
MXPA06012613A (es) 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
RU2410384C2 (ru) 2004-06-17 2011-01-27 Цитокинетикс, Инк. Соединения, композиции и способы их использования
WO2006009729A2 (fr) 2004-06-18 2006-01-26 Medtronic, Inc. Procedes et dispositifs d'occlusion d'un appendice auriculaire
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2006089871A2 (fr) 2005-02-23 2006-08-31 Neurosearch A/S Derives de diphenyluree utiles en tant qu'agents d'ouverture de canal erg pour le traitement d'arythmies cardiaques
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070197505A1 (en) 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959960B1 (fr) 2005-12-15 2013-04-10 Cytokinetics, Inc. Entites chimiques, compositions et procedes
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959962A2 (fr) 2005-12-16 2008-08-27 Cytokinetics, Inc. Entites chimiques, compositions et methodes
EP1962852B1 (fr) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Composes, compositions et methodes
US7672247B2 (en) * 2006-02-23 2010-03-02 International Business Machines Corporation Evaluating data processing system health using an I/O device

Also Published As

Publication number Publication date
US10035770B2 (en) 2018-07-31
US20090036447A1 (en) 2009-02-05
EP2862859A3 (fr) 2015-05-06
US20150005296A1 (en) 2015-01-01
AU2005264988A1 (en) 2006-01-26
US20170267638A1 (en) 2017-09-21
US20120172372A1 (en) 2012-07-05
RS53600B1 (en) 2015-02-27
US8101617B2 (en) 2012-01-24
EP1765327A2 (fr) 2007-03-28
CA2570999A1 (fr) 2006-01-26
US20180305316A1 (en) 2018-10-25
US10975034B2 (en) 2021-04-13
WO2006009726A2 (fr) 2006-01-26
JP2008503467A (ja) 2008-02-07
NZ552404A (en) 2010-04-30
BRPI0512193B8 (pt) 2021-05-25
JP2012097093A (ja) 2012-05-24
PL1765327T3 (pl) 2015-01-30
CN101035525A (zh) 2007-09-12
US20090099198A1 (en) 2009-04-16
ME01942B (me) 2015-05-20
KR101276136B1 (ko) 2013-06-18
US7507735B2 (en) 2009-03-24
US20220185779A1 (en) 2022-06-16
ZA200700351B (en) 2008-05-28
US8513257B2 (en) 2013-08-20
SG149027A1 (en) 2009-01-29
SI1765327T1 (sl) 2014-12-31
US20140038983A1 (en) 2014-02-06
AR053405A1 (es) 2007-05-09
BRPI0512193A (pt) 2008-02-19
US20160115133A1 (en) 2016-04-28
PT1765327E (pt) 2014-11-24
RU2007101619A (ru) 2008-08-10
CA2570999C (fr) 2014-01-07
DK1765327T3 (da) 2014-11-03
US9150564B2 (en) 2015-10-06
IL180026A0 (en) 2007-05-15
HK1101060A1 (en) 2007-10-05
HRP20141048T1 (hr) 2015-01-02
US10385023B2 (en) 2019-08-20
DK2862859T3 (en) 2018-08-13
ES2686357T3 (es) 2018-10-17
PL216049B1 (pl) 2014-02-28
ECSP077180A (es) 2007-04-26
AU2005264988B2 (en) 2011-09-22
BRPI0512193B1 (pt) 2018-11-21
KR20070046070A (ko) 2007-05-02
NO20070257L (no) 2007-01-16
PL381801A1 (pl) 2007-07-09
US9643925B2 (en) 2017-05-09
US20190352267A1 (en) 2019-11-21
JP5080970B2 (ja) 2012-11-21
HK1209729A1 (en) 2016-04-08
EP1765327B1 (fr) 2014-08-13
TW200616996A (en) 2006-06-01
IL180026A (en) 2011-11-30
US8110595B2 (en) 2012-02-07
ES2522579T3 (es) 2014-11-17
NO340030B1 (no) 2017-02-27
TWI359812B (en) 2012-03-11
US20210198203A1 (en) 2021-07-01
EA200700058A1 (ru) 2007-08-31
EP1765327A4 (fr) 2009-06-17
RU2410384C2 (ru) 2011-01-27
MXPA06014495A (es) 2007-03-01
CY1115716T1 (el) 2017-01-25
US20060014761A1 (en) 2006-01-19
MY144470A (en) 2011-09-30
EP2862859B1 (fr) 2018-07-25
US8871769B2 (en) 2014-10-28
EP2862859A2 (fr) 2015-04-22
PE20060438A1 (es) 2006-07-01
WO2006009726A3 (fr) 2006-11-30
EA016138B1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
MA28738B1 (fr) Composes, compositions et procedes associes
MXPA05007513A (es) Compuestos, composiciones y metodos.
WO2007078815A3 (fr) Entites chimiques, compositions et methodes
EP1605752A4 (fr) Composes, compositions et methodes
WO2007089336A3 (fr) Différentes entités compositions et méthodes chimiques
WO2007078839A3 (fr) Composes, compositions et methodes
WO2007070683A3 (fr) Entites chimiques, compositions et procedes
WO2007070626A3 (fr) Entites chimiques, compositions et procedes
EA200700142A1 (ru) Замещенные гетероциклом циклические производные мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
NO20070089L (no) DPP-IV inhibitorer
EA201000558A1 (ru) Производные имидазола
NO20063676L (no) Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer
DE602006015671D1 (de) Kokumi-geschmackverbindungen und ihre verwendung
EA201000550A1 (ru) Производные тиазола
MX340714B (es) Inhibidores de hsp90.
MX2008001538A (es) Aril piridinas y metodos para su uso.
ATE519378T1 (de) Verbindungen mit kokumi-geschmack und ihre verwendung
WO2003059258A3 (fr) Compositions et methodes permettant de traiter l&#39;insuffisance cardiaque
EA201100872A1 (ru) Производные хиназолинамида
WO2003059265A3 (fr) Compositions et procedes de traitement de l&#39;insuffisance cardiaque
EA201170015A1 (ru) Производные 2-оксоалкил-1-пиперазин-2-она, их получение и их применение в терапии
NO20085412L (no) Pyrrolidinderivater som har aktivitet ved GLYT1 transportoren
ATE453628T1 (de) Nucleosidderivate und deren therapeutische verwendung
EA200700692A1 (ru) Пиридиновые производные индолин-2-она, их получение и их прменение в терапии
NO20081529L (no) Naftyridinderivater